ANP Licensing Partner Strongbridge Announces Pricing of IPO
Filed with ASX · · 3 pages · English
Percheron Therapeutics Limited on 6ix
Later from Percheron Therapeutics
- ATL1103 Data Presentation at Scientific Conference
- COR-004/ATL1103 Project Update
- ATL1102 for MS FDA Response to Phase IIb Study Plans
- ATL1103 Deed of Settlement, Termination and Transfer
- ATL1103 Higher Dose Study - Update
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics